Search research articles
Contact Us
Filters
Showing results (101-110 of 225) with videos related to
Page
of 23
Sort By:
Der Nervenarzt
|
September 14, 1999
[Interferon beta-1b for treatment of secondary chronic progressive multiple sclerosis]
C Zimmermann, E U Walther, N Goebels, et al.
Revue Neurologique
|
September 9, 2005
[Sclerotic plaques and hepatitis B vaccination in adults: the situation in 2004. Response]
C Confavreux, S Vukusic, T Arbizu, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
January 1, 1996
Hereditary defect of cobalamin metabolism (homocystinuria and methylmalonic aciduria) of juvenile onset
R Gold, U Bogdahn, L Kappos, et al.
Klinische Monatsblatter Fur Augenheilkunde
|
May 6, 2008
Pattern of macular thickness changes measured by ocular coherence tomography in patients with multiple sclerosis
K Gugleta, M Mehling, A Kochkorov, et al.
Leukemia & Lymphoma
|
January 1, 1996
Fatal vascular leak syndrome with extensive hemorrhage, peripheral neuropathy and reactive erythrophagocytosis: an unusual complication of recombinant IL-3 therapy
N Hurwitz, A Probst, G Zufferey, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
August 21, 2003
Oral interferon beta-1a in relapsing-remitting multiple sclerosis: a double-blind randomized study
C Polman, F Barkhof, L Kappos, et al.
Neurology
|
May 14, 2003
MRI metrics as surrogate endpoints for EDSS progression in SPMS patients treated with IFN beta-1b
M P Sormani, P Bruzzi, K Beckmann, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
July 18, 2008
Neuropsychological dysfunction, depression, physical disability, and coping processes in families with a parent affected by multiple sclerosis
M M Ehrensperger, A Grether, G Romer, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical
|
December 26, 2017
Subcutaneous interferon β-1a three times weekly and the natural evolution of gadolinium-enhancing lesions into chronic black holes in relapsing and progressive multiple sclerosis: Analysis of PRISMS and SPECTRIMS trials
A Traboulsee, Dkb Li, R Tam, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
January 1, 1995
Interferon beta-1b in secondary progressive multiple sclerosis--outline of the clinical trial
C H Polman, F Dahlke, A J Thompson, et al.
Page
of 23
Search research articles
Search
Showing results (101-110 of 225) with videos related to
Sort By:
Page
of 23
Der Nervenarzt
|
September 14, 1999
[Interferon beta-1b for treatment of secondary chronic progressive multiple sclerosis]
C Zimmermann, E U Walther, N Goebels, et al.
Revue Neurologique
|
September 9, 2005
[Sclerotic plaques and hepatitis B vaccination in adults: the situation in 2004. Response]
C Confavreux, S Vukusic, T Arbizu, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
January 1, 1996
Hereditary defect of cobalamin metabolism (homocystinuria and methylmalonic aciduria) of juvenile onset
R Gold, U Bogdahn, L Kappos, et al.
Klinische Monatsblatter Fur Augenheilkunde
|
May 6, 2008
Pattern of macular thickness changes measured by ocular coherence tomography in patients with multiple sclerosis
K Gugleta, M Mehling, A Kochkorov, et al.
Leukemia & Lymphoma
|
January 1, 1996
Fatal vascular leak syndrome with extensive hemorrhage, peripheral neuropathy and reactive erythrophagocytosis: an unusual complication of recombinant IL-3 therapy
N Hurwitz, A Probst, G Zufferey, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
August 21, 2003
Oral interferon beta-1a in relapsing-remitting multiple sclerosis: a double-blind randomized study
C Polman, F Barkhof, L Kappos, et al.
Neurology
|
May 14, 2003
MRI metrics as surrogate endpoints for EDSS progression in SPMS patients treated with IFN beta-1b
M P Sormani, P Bruzzi, K Beckmann, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
July 18, 2008
Neuropsychological dysfunction, depression, physical disability, and coping processes in families with a parent affected by multiple sclerosis
M M Ehrensperger, A Grether, G Romer, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical
|
December 26, 2017
Subcutaneous interferon β-1a three times weekly and the natural evolution of gadolinium-enhancing lesions into chronic black holes in relapsing and progressive multiple sclerosis: Analysis of PRISMS and SPECTRIMS trials
A Traboulsee, Dkb Li, R Tam, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
January 1, 1995
Interferon beta-1b in secondary progressive multiple sclerosis--outline of the clinical trial
C H Polman, F Dahlke, A J Thompson, et al.
Page
of 23